Aquestive Therapeutics, Inc. - Common Stock (AQST)

Competitors to Aquestive Therapeutics, Inc. - Common Stock (AQST)

Evoke Pharma, Inc. 

Evoke Pharma, Inc. focuses on treating diabetic gastroparesis with its drug Gimoti, which offers a nasal delivery system for a treatment that is traditionally taken orally. This approach directly competes with Aquestive's focus on drug delivery and formulations that improve patient compliance. Both companies aim at enhancing therapeutic applications using innovative delivery mechanisms, but Evoke's niche indication might limit broader competition. However, its focused market strategy and patient-centric approach could give it an edge in specialized treatments.

NantKwest, Inc.

NantKwest, Inc. operates in the biopharmaceutical sector with a focus on immunotherapy and related therapies for cancer treatment. While not a direct competitor in terms of drug formulation technology, its cutting-edge therapeutic strategies could intersect with Aquestive's market if they decide to advance into similar CNS indications or drug delivery mechanisms. Their strength lies in a robust pipeline and pioneering approaches in immuno-oncology, which could overshadow the more conventional delivery methods that Aquestive employs.

Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc. specializes in transdermal cannabinoid therapies for a variety of conditions, including behavioral issues in autism and pain. While their primary focus on cannabinoid therapies diverges from Aquestive's broader range of drug development for CNS disorders, they both tackle delivery systems aimed at ensuring better bioavailability and patient adherence. Zynerba's advantage lies in the growing acceptance and clinical exploration of cannabinoid-based treatments, which could position it favorably as public perception shifts towards alternative therapies.